Search Results - "Foppen, Marnix Geukes"

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma by Van Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk, Garraway, Levi A.

“…Monoclonal antibodies directed against cytotoxic T lymphocyte–associated antigen-4 (CTLA-4), such as ipilimumab, yield considerable clinical benefit for…”
Get full text

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch by Kong, Xiangjun, Kuilman, Thomas, Shahrabi, Aida, Boshuizen, Julia, Kemper, Kristel, Song, Ji-Ying, Niessen, Hans W. M., Rozeman, Elisa A., Geukes Foppen, Marnix H., Blank, Christian U., Peeper, Daniel S.

“…The identification of an ERK2–JUNB–FRA1 signalling pathway that drives addiction to therapeutic drugs in cancer cells, and an ERK2-dependent phenotype switch…”
Get full text

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma by Müller, Judith, Krijgsman, Oscar, Tsoi, Jennifer, Robert, Lidia, Hugo, Willy, Song, Chunying, Kong, Xiangju, Possik, Patricia A., Cornelissen-Steijger, Paulien D. M., Foppen, Marnix H Geukes, Kemper, Kristel, Goding, Colin R., McDermott, Ultan, Blank, Christian, Haanen, John, Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Peeper, Daniel S.

“…Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway…”
Get full text

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management by Geukes Foppen, Marnix H, Rozeman, Elisa A, van Wilpe, Sandra, Postma, Cindy, Snaebjornsson, Petur, van Thienen, Johannes V, van Leerdam, Monique E, van den Heuvel, Michel, Blank, Christian U, van Dieren, Jolanda, Haanen, John B A G

“…BackgroundImmune checkpoint inhibitors are successfully introduced as anticancer treatment. However, they may induce severe immune-related adverse events…”
Get full text

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis by Schilling, Bastian, Martens, Alexander, Geukes Foppen, Marnix H., Gebhardt, Christoffer, Hassel, Jessica C., Rozeman, Elisa A., Gesierich, Anja, Gutzmer, Ralf, Kähler, Katharina C., Livingstone, Elisabeth, Diamantopoulos, Panagiotis T., Gogas, Helen, Madonna, Gabriele, Ascierto, Paolo A., Goldinger, Simone M., Mangana, Johanna, Garbe, Claus, Schadendorf, Dirk, Blank, Christian, Weide, Benjamin

“…Background Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong…”
Get full text

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation by Retèl, Valesca P, Steuten, Lotte M G, Geukes Foppen, Marnix H, Mewes, Janne C, Lindenberg, Melanie A, Haanen, John B A G, van Harten, Wim H

“…An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an…”
Get full text

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma by Deken, Marcel A., Gadiot, Jules, Jordanova, Ekaterina S., Lacroix, Ruben, van Gool, Melissa, Kroon, Paula, Pineda, Cristina, Geukes Foppen, Marnix H., Scolyer, Richard, Song, Ji-Ying, Verbrugge, Inge, Hoeller, Christoph, Dummer, Reinhard, Haanen, John B. A. G., Long, Georgina V., Blank, Christian U.

“…Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a proportion of patients long durable responses. In contrast,…”
Get full text

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma by Geukes Foppen, Marnix H, Boogerd, Willem, Blank, Christian U, van Thienen, Johannes V, Haanen, John B, Brandsma, Dieta

“…Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an…”
Get full text

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up by van den Berg, Joost H, Heemskerk, Bianca, van Rooij, Nienke, Gomez-Eerland, Raquel, Michels, Samira, van Zon, Maaike, de Boer, Renate, Bakker, Noor A M, Jorritsma-Smit, Annelies, van Buuren, Marit M, Kvistborg, Pia, Spits, Hergen, Schotte, Remko, Mallo, Henk, Karger, Matthias, van der Hage, Joris A, Wouters, Michel W J M, Pronk, Loes M, Geukes Foppen, Marnix H, Blank, Christian U, Beijnen, Jos H, Nuijen, Bastiaan, Schumacher, Ton N, Haanen, John B A G

“…Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably…”
Get full text

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial by de Gooyer, Peter G. M., Verschoor, Yara L., van den Dungen, Lauren D. W., Balduzzi, Sara, Marsman, Hendrik A., Geukes Foppen, Marnix H., Grootscholten, Cecile, Dokter, Simone, den Hartog, Anne G., Verbeek, Wieke H. M., Woensdregt, Karlijn, van den Broek, Joris J., Oosterling, Steven J., Schumacher, Ton N., Kuhlmann, Koert F. D., Beets-Tan, Regina G. H., Haanen, John B. A. G., van Leerdam, Monique E., van den Berg, Jose G., Chalabi, Myriam

“…Mismatch repair deficiency (dMMR) is found in approximately 15% of non-metastatic colon cancers (CCs) and is characterized by a defective DNA mismatch repair…”
Get full text

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma by Peters, Marieke, Geukes Foppen, Marnix, Blank, Christian, Crijns, Marianne

“…With the discovery of v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors, new treatment possibilities arose against metastatic melanoma. A…”
Get full text

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product by Lindenberg, Melanie A, Retèl, Valesca P, van den Berg, Joost H, Geukes Foppen, Marnix H, Haanen, John B, van Harten, Wim H

“…Tumor-infiltrating lymphocytes (TIL)-therapy in advanced melanoma is an advanced therapy medicinal product (ATMP) which, despite promising results, has not…”
Get full text

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab by Martens, Alexander, Wistuba-Hamprecht, Kilian, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael A, Wong, Phillip, Romano, Emanuela, Khammari, Amir, Dreno, Brigitte, Capone, Mariaelena, Ascierto, Paolo A, Di Giacomo, Anna Maria, Maio, Michele, Schilling, Bastian, Sucker, Antje, Schadendorf, Dirk, Hassel, Jessica C, Eigentler, Thomas K, Martus, Peter, Wolchok, Jedd D, Blank, Christian, Pawelec, Graham, Garbe, Claus, Weide, Benjamin

“…To identify baseline peripheral blood biomarkers associated with clinical outcome following ipilimumab treatment in advanced melanoma patients. Frequencies of…”
Get full text

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination by Boudewijns, Steve, Koornstra, Rutger H. T., Westdorp, Harm, Schreibelt, Gerty, van den Eertwegh, Alfons J. M., Geukes Foppen, Marnix H., Haanen, John B., de Vries, I. Jolanda M., Figdor, Carl G., Bol, Kalijn F., Gerritsen, Winald R.

“…Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in…”
Get full text

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients by Wistuba-Hamprecht, Kilian, Martens, Alexander, Heubach, Florian, Romano, Emanuela, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael, Wong, Phillip, Mallardo, Domenico, Schilling, Bastian, Di Giacomo, Anna Maria, Khammari, Amir, Dreno, Brigitte, Maio, Michele, Schadendorf, Dirk, Ascierto, Paolo A, Wolchok, Jedd D, Blank, Christian U, Garbe, Claus, Pawelec, Graham, Weide, Benjamin

“…Abstract The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we…”
Get full text

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab by Wistuba-Hamprecht, Kilian, Martens, Alexander, Haehnel, Karin, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael A, Wong, Phillip, Romano, Emanuela, Khammari, Amir, Dreno, Brigitte, Capone, Mariaelena, Ascierto, Paolo A, Demuth, Ilja, Steinhagen-Thiessen, Elisabeth, Larbi, Anis, Schilling, Bastian, Schadendorf, Dirk, Wolchok, Jedd D, Blank, Christian U, Pawelec, Graham, Garbe, Claus, Weide, Benjamin

“…Abstract Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the…”
Get full text

Practical implications of liver and heart iron load assessment by T2‐MRI in children and adults with transfusion‐dependent anemias by Deborah Chirnomas, Sarah, Geukes‐Foppen, Marnix, Barry, Kristen, Braunstein, Jennifer, Kalish, Leslie A., Neufeld, Ellis J., Powell, Andrew J.

“…This study examined the relationship between hepatic and myocardial iron concentration, assessed by T2*‐MRI in 66 patients (3–82 years) with…”
Get full text

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors by Boshuizen, Julia, Koopman, Louise A, Krijgsman, Oscar, Shahrabi, Aida, van den Heuvel, Elke Gresnigt–, Ligtenberg, Maarten A, Vredevoogd, David W, Kemper, Kristel, Kuilman, Thomas, Song, Ji-Ying, Pencheva, Nora, Mortensen, Jens Thing, Foppen, Marnix Geukes, Rozeman, Elisa A, Blank, Christian U, Janmaat, Maarten L, Satijn, David, Breij, Esther C W, Peeper, Daniel S, Parren, Paul W H I

“…Expression of AXL earmarks melanoma cells resistant to BRAF and MEK inhibitors that either pre-exist in treatment-naive tumors or emerge in response to…”
Get full text

Correlation between baseline parameters and overall survival in patients with advanced melanoma treated with ipilimumab by Geukes Foppen, Marnix Heimen, Jordanova, Ekatarina S., Van Thienen, Johannes V., Punt, Simone, Van De Wiel, Bart, Haanen, John B. A. G., Blank, Christian U.

“…Abstract only 9572 Background: Checkpoint inhibitors (IT) have revolutionized treatment options for patients (pts) with advanced melanoma. Recently, we…”
Get full text

Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4 by Rozeman, Elisa A., Geukes Foppen, Marnix Heimen, Ong, SuFey, Lacroix, Ruben, Danaher, Patrick, Broeks, Annegien, Cesano, Alessandra, Wilgenhof, Sofie, Van Thienen, Johannes V., Haanen, John B. A. G., Warren, Sarah, Blank, Christian U.

“…Abstract only…”
Get full text